TFF Pharma's Inhaled Niclosamide Shows Potent Activity Against Omicron Variant

Preclinical studies show that TFF Pharmaceuticals Inc's TFFP inhaled niclosamide product candidate inhibits viral replication of both the Delta and Omicron variants of SARS-CoV-2.

• More specifically, nirmatrelvir and molnupiravir showed complete inhibition of the Omicron variant at 2.5 μM.
• In the studies announced today by TFF Pharmaceuticals, inhaled niclosamide demonstrated complete inhibition of Omicron at only 1μM. 
• These studies also confirm the previous findings, which validated the potent antiviral efficacy of niclosamide in a human airway model.
• Related: TFF Pharma To Begin Human Trial For Inhaled COVID-19 Therapy In Canada.
• In a Phase 1 study, TFF Pharmaceuticals has already demonstrated that a 6 mg BID dosing of inhaled niclosamide is well tolerated. Notably, the 6 mg dose level is estimated to produce a concentration of >100 μM in the epithelial lining fluid in the lung following delivery as a dry powder.
• TFF Pharmaceuticals has completed enrollment in the Phase 1 study of its inhaled formulation of niclosamide for COVID-19. It expects to release the safety and pharmacokinetic data by the end of Q1 of 2022.
• Price Action: TFFP shares are up 6.42% at $6.30 during the market session on the last check Thursday.